More than 7 years – that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
